| Literature DB >> 22166846 |
Jeffrey M Turner1, Carolyn Bauer, Matthew K Abramowitz, Michal L Melamed, Thomas H Hostetter.
Abstract
Treatment of chronic kidney disease (CKD) can slow its progression to end-stage renal disease (ESRD). However, the therapies remain limited. Blood pressure control using angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) has the greatest weight of evidence. Glycemic control in diabetes seems likely to retard progression. Several metabolic disturbances of CKD may prove to be useful therapeutic targets but have been insufficiently tested. These include acidosis, hyperphosphatemia, and vitamin D deficiency. Drugs aimed at other potentially damaging systems and processes, including endothelin, fibrosis, oxidation, and advanced glycation end products, are at various stages of development. In addition to the paucity of proven effective therapies, the incomplete application of existing treatments, the education of patients about their disease, and the transition to ESRD care remain major practical barriers to better outcomes.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22166846 DOI： 10.1038/ki.2011.380
Source DB: PubMed Journal: Kidney Int ISSN： 0085-2538 Impact factor: 10.612